

## FINANCIAL SUPERVISION AUTHORITY

Current report No. 42/2018

Date prepared: 11/06/2018

Abbreviated name of the issuer:

MABION S.A.

Subject

Signing the grant agreement on the project of the building extension of the Research and Development Center of Mabion S.A.

Legal basis

Art. 17 sec. 1 of the Market Abuse Regulation (MAR) – confidential information

Content of the report:

In regard to the current report no. 22/2018 of 4<sup>th</sup> April 2018 on the choice for the grant on “Building extension of the Research and Development Center of Mabion S.A.– research on a new generation of medicinal drugs” \_ “the Project” \_ within Action 2.1. Support for investments in R&D infrastructure of enterprises of the Smart Growth Operational Program 2014-2020, co-financed from the European Regional Development Fund, the Board of Mabion S.A. (“the Company”) hereby informs that on 11<sup>th</sup> June 2018 it signed the project grant agreement with the Minister of Investment and Economic Development.

The Company reminds that the subject of the Project is development of the research and development background of the Company by preparation of the necessary infrastructure: building of the R&D Center and purchase of research equipment for research conducted on innovative medicinal drugs. The designed R&D Center is designated as a place for development and preparation for commercial release of the newest generation of biotechnological medicinal drugs, monoclonal antibodies.

Total cost of the Project was estimated as PLN 172,88 million, while the value of the grant is PLN 63,25 million.